These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 12708222)

  • 1. Long-term cholinesterase inhibitor therapy for Alzheimer's disease: implications for long-term care.
    Brangman SA
    Am J Alzheimers Dis Other Demen; 2003; 18(2):79-84. PubMed ID: 12708222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donepezil can improve daily activities and promote rehabilitation for severe Alzheimer's patients in long-term care health facilities.
    Meguro K; Ouchi Y; Akanuma K; Meguro M; Kasai M
    BMC Neurol; 2014 Dec; 14():243. PubMed ID: 25516360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Alzheimer's disease in the long-term-care setting.
    Smith DA
    Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-Term Response to Cholinesterase Inhibitors in Alzheimer's Disease Delays Time to Nursing Home Placement.
    Wattmo C; Londos E; Minthon L
    Curr Alzheimer Res; 2018; 15(10):905-916. PubMed ID: 29732972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donepezil for dementia due to Alzheimer's disease.
    Birks JS; Harvey RJ
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donepezil use for advanced Alzheimer's disease--a case study from a long-term care facility.
    Tariot PN; Jakimovich L
    J Am Med Dir Assoc; 2003; 4(4):216-9. PubMed ID: 12837144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solitary living in Alzheimer's disease over 3 years: association between cognitive and functional impairment and community-based services.
    Wattmo C; Londos E; Minthon L
    Clin Interv Aging; 2014; 9():1951-62. PubMed ID: 25484578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease: a prospective, observational study of factors affecting survival time from admission to death.
    Wattmo C; Londos E; Minthon L
    BMC Neurol; 2016 Aug; 16(1):156. PubMed ID: 27581368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
    Wattmo C; Wallin ÅK
    Alzheimers Res Ther; 2017 Aug; 9(1):70. PubMed ID: 28859660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Care of individuals with Alzheimer's disease in the new millennium.
    Souder E; Rapp CG; Davis GV; Beck C; Liem PH
    Medsurg Nurs; 2004 Feb; 13(1):22-31. PubMed ID: 15029928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinesterase inhibitors for Alzheimer's disease.
    Birks J
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD005593. PubMed ID: 16437532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of clinical treatment considerations of donepezil in severe Alzheimer's disease.
    Adlimoghaddam A; Neuendorff M; Roy B; Albensi BC
    CNS Neurosci Ther; 2018 Oct; 24(10):876-888. PubMed ID: 30058285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.
    Winblad B; Kilander L; Eriksson S; Minthon L; Båtsman S; Wetterholm AL; Jansson-Blixt C; Haglund A;
    Lancet; 2006 Apr; 367(9516):1057-1065. PubMed ID: 16581404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.
    Fullerton T; Binneman B; David W; Delnomdedieu M; Kupiec J; Lockwood P; Mancuso J; Miceli J; Bell J
    Alzheimers Res Ther; 2018 Apr; 10(1):38. PubMed ID: 29622037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
    Green C; Picot J; Loveman E; Takeda A; Kirby J; Clegg A
    Pharmacoeconomics; 2005; 23(12):1271-82. PubMed ID: 16336020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
    Courtney C; Farrell D; Gray R; Hills R; Lynch L; Sellwood E; Edwards S; Hardyman W; Raftery J; Crome P; Lendon C; Shaw H; Bentham P;
    Lancet; 2004 Jun; 363(9427):2105-15. PubMed ID: 15220031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
    Wattmo C; Minthon L; Wallin ÅK
    Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.